Paul de Klaver

Mr. Paul de Klaver

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2009 in Acta Orthopaedica
Verified
Journal Article
Open access
PDF file
PKPaul de Klaver
Paul de Klaver
JKJan de Koning
Jan de Koning
RJRob Janssen
Rob Janssen
LDLuc J J Derijks
Luc J J Derijks
Gentamicin beads are used for musculoskeletal infections. Gentamicin is released gradually from the beads, and high gentamicin concentrations are achieved only locally. Side effects of gentamicin a...

15 June 2023 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
PKPaul de Klaver
Paul de Klaver
RKRon J. Keizer
Ron J. Keizer
RHRob ter Heine
Rob ter Heine
LSLisa Smits
Lisa Smits
PBPaul J. Boekema
Paul J. Boekema
LDLuc J. J. Derijks
Luc J. J. Derijks

12 April 2022 in arXiv
Verified
Preprint
Open access
PDF file
STSander Tonkens
Sander Tonkens
PKPaul de Klaver
Paul de Klaver
MSMauro Salazar
Mauro Salazar
Since early 2020, the world has been dealing with a raging pandemic outbreak: COVID-19. A year later, vaccines have become accessible, but in limited quantities, so that governments needed to devise a strategy to decide which part of the population to prioritize when assigning the available doses, and how to manage the interval between doses for multi-dose vaccines. In this paper, we present an optimization framework to address the dynamic double-dose vaccine allocation problem whereby the available vaccine doses must be administered to different age-groups to minimize specific societal objectives. In particular, we first identify an age-dependent Susceptible-Exposed-Infected-Recovered (SEIR) epidemic model including an extension capturing partially and fully vaccinated people, whereby we account for age-dependent immunity and infectiousness levels together with disease severity. Second, we leverage our model to frame the dynamic age-dependent vaccine allocation problem for different societal objectives, such as the minimization of infections or fatalities, and solve it with nonlinear programming techniques. Finally, we carry out a numerical case study with real-world data from The Netherlands. Our results show how different societal objectives can significantly alter the optimal vaccine allocation strategy. For instance, we find that minimizing the overall number of infections results in delaying second doses, whilst to minimize fatalities it is important to fully vaccinate the elderly first.

27 July 2022 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
PKPaul de Klaver
Paul de Klaver
CGCarolien M. Geesink
Carolien M. Geesink
JBJasper C. A. Broen
Jasper C. A. Broen
LDLuc J. J. Derijks
Luc J. J. Derijks

22 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PKPaul de Klaver
Paul de Klaver
AWAmber M. H. van Woerkens
Amber M. H. van Woerkens
HDHedwig Maria Antonia D'Agnolo
Hedwig Maria Antonia D'Agnolo
MPMarieke J. Pierik
Marieke J. Pierik
L.J.J. (Luc) DerijksL.J.J. (Luc) Derijks
L.J.J. (Luc) Derijks
Background/Objectives: Two clinical decision support tools (CDSTs) have been developed to predict treatment effectiveness of vedolizumab in Crohn’s disease (CD) and ulcerative colitis (UC). This study aimed to validate the CDSTs with real-world data from a Dutch teaching hospital. Methods: Patients with CD or UC treated with vedolizumab between October 2014 and July 2023 were included. IBD patients treated with ustekinumab were included to study the specificity of the CDSTs. The primary outcomes were rates of clinical remission (CREM), biochemical remission (BioREM), composite (either clinical or biochemical) remission (CompREM) and corticosteroid-free clinical remission (CSF-CREM) at week 14, 30 and 54. Results: 32 CD patients and 41 UC patients treated with vedolizumab were included, as well as 28 CD patients treated with ustekinumab and 41 UC patients treated with vedolizumab. Among UC patients treated with vedolizumab, rates of CREM, CompREM and CSF-CREM at week 54 were statistically significantly higher in the group with high probability of response compared to the group with low + intermediate probability of response (CREM 33.3% vs. 81.8% p = 0.003; CompREM 33.3% vs. 86.4% p < 0.001; CSF-CREM 22.2% vs. 77.3% p = 0.001). For both CD patients treated with vedolizumab and CD patients treated with ustekinumab, no statistically significant differences were found between low + intermediate and high probability groups for all outcomes. Conclusions: The CDST for UC is able to predict various effectiveness outcomes for treatment with vedolizumab and can therefore help in the selection of optimal treatment for patients with UC. For CD patients treated with vedolizumab, the CDST could not predict effectiveness outcomes.

31 January 2024
Verified
Preprint
Open access
PKPaul de Klaver
Paul de Klaver
RKRon Keizer
Ron Keizer
RHRob ter Heine
Rob ter Heine
FHFrank Hoentjen
Frank Hoentjen
PBPaul Boekema
Paul Boekema
LDLuc Derijks
Luc Derijks
1. Aims Underdosing of adalimumab can result in non-response and poor disease control. In this study we investigated the prediction of adalimumab levels with population pharmacokinetic model-based Bayesian forecasting early in therapy. This way underexposed non-responders can possibly be identified early to optimise disease control. 2. Methods A literature study was performed to identify adalimumab pharmacokinetic models. With data from a previous pharmacokinetic adalimumab study a model was evaluated retrospectively. In the prospective phase, a fit-for-purpose evaluation of the model was performed for rheumatologic and inflammatory bowel disease patients with peak, trough and control adalimumab samples obtained by a volumetric absorptive microsampling technique and administration data from an electronic needle container. Steady state adalimumab levels were predicted from peak and trough levels collected after the first adalimumab administration. Predictive performance was calculated with mean prediction error (MPE) and normalized root mean square error (RMSE). 3. Results An existing pharmacokinetic model was selected with external validation for the prospective phase. Thirty-six patients (22 rheumatologic and 14 IBD) were included in our study. After stratification for absence of anti-adalimumab antibodies, the calculated MPE was -2.6% and normalised RMSE 24.0%. Concordance between predicted and measured adalimumab serum levels falling within or outside the therapeutic window was 75%. Three patients (8.3%) developed detectable levels of anti-adalimumab antibodies. 4. Conclusion This prospective study demonstrates that adalimumab levels at steady state can be predicted from early samples. This concept enables early precision dosing at home to guide therapy.